Apogee Therapeutics, Inc.
APGE
Clasificación en acciones
#2356
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Precio por acción
$135.07
Última sincronización: 2026-09-04
Capitalización bursátil
$8.36B
Cambio (1 día)
0.00%
Cambio (1 año)
144.91%
País
US
Comercio Apogee Therapeutics, Inc. (APGE)
Categoría
Healthcare
EPS de Apogee Therapeutics, Inc. (APGE)
EPS a fecha de June 2026 TTM: $-4.34
Según los últimos informes financieros y el precio de las acciones de Apogee Therapeutics, Inc., el EPS actual de la empresa (TTM) es $-4.34. Al final del año 2023, la empresa tenía un EPS de $-1.66 un aumento con respecto a al EPS de 2022, que fue de $-0.79.
Historial de EPS de Apogee Therapeutics, Inc. desde 2022 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
